BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 25056472)

  • 1. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
    Zhao SJ; Liu JY; Ren FR; Feng YJ
    Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):264-8. PubMed ID: 15924676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
    Rodabaugh KJ; Mhawech-Fauceglia P; Groth J; Lele S; Sood AK
    Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
    Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
    Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of THY1 gene in epithelial ovarian cancer].
    Zeng LQ; Peng ZL; Duan ZL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
    Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.